Tag Archives: Lexicon Pharmaceuticals

The President & CEO of Lexicon Pharmaceuticals (NASDAQ: LXRX) is Buying Shares

Today, the President & CEO of Lexicon Pharmaceuticals (LXRX – Research Report), Lonnel Coats, bought shares of LXRX for $155K. Following this transaction Lonnel Coats’ holding in the company was increased by 28.16% to a total of $864.6K. In addition

A Director at Lexicon Pharmaceuticals (NASDAQ: LXRX) is Buying Shares

Yesterday, a Director at Lexicon Pharmaceuticals (LXRX – Research Report), Raymond Debbane, bought shares of LXRX for $474.7K. This recent transaction increases Raymond Debbane’s holding in the company by 4.77% to a total of $13.63 million. In addition to Raymond

Lexicon Pharmaceuticals (LXRX) Gets a Hold Rating from Needham

Needham analyst Alan Carr maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed last Monday at $1.72, close to its 52-week low of $1.13. According to TipRanks.com, Carr is a 3-star analyst with

The VP, Finance & Accounting of Lexicon Pharmaceuticals (NASDAQ: LXRX) is Buying Shares

Yesterday, the VP, Finance & Accounting of Lexicon Pharmaceuticals (LXRX – Research Report), James Tessmer, bought shares of LXRX for $11.4K. Following this transaction James Tessmer’s holding in the company was increased by 29.97% to a total of $52.04K. In

Wedbush Thinks Lexicon Pharmaceuticals’ Stock is Going to Recover

Wedbush analyst Liana Moussatos reiterated a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price target of $35. The company’s shares opened today at $5.38, close to its 52-week low of $4.25. According to TipRanks.com,

Needham Remains a Hold on Lexicon Pharmaceuticals (LXRX)

Needham analyst Alan Carr maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) yesterday. The company’s shares closed yesterday at $5.97. Carr noted: “Lexicon reported 1Q19 U.S. Xermelo sales of $6.7M, below our $8.0M est. Mgmt reiterated 2019